IL22 and graft versus host disease: Thus, through IL-22 production, ILC3s not only favor epithelial regeneration protecting the recipient from GvHD, but also contribute to the restoration of adaptive immunity, which is a critical determinant of successful outcomes in allogenic HSCT.